GCKR and metabolic disease: CRP is the prototype acute-phase reactant and a hallmark of low-grade systemic inflammation, thus it has been assumed that chronic low-grade systemic inflammation mediates the effect of the GCKR variant on complex metabolic diseases, including NAFLD.